source
- Novo Nordisk CFO sees oral Wegovy rollout boosting outlook and remains upbeat on CagriSemaNovo Nordisk's chief financial officer, Karsten Munk Knudsen, discussed the company's second‑quarter earnings and the progress of the oral Wegovy pill during a recent interview. He highlighted that…
- Replimune secures FDA approval for Tudriqev, eyes $1.3 bn peak sales in advanced melanomaReplimune announced FDA approval of its therapy Tudriqev for patients with advanced melanoma who have progressed after PD-1 treatment. Analysts at BMO Capital Markets project the drug could genera…